What are the functions and efficacy of Besudil mesylate tablets?

Belumosudil mesylate tablets (Belumosudil) is a selective Rho-related protein kinase 2 (ROCK2) inhibitor. Its main function is to regulate signaling pathways in the immune system, thus exerting dual effects of anti-inflammatory and anti-fibrosis. It was originally developed to target chronic graft-versus-host disease (cGVHD), a complex and stubborn immune complication, and its unique mechanism also gives it the potential to expand its application in other diseases related to immune disorders.

The main function of Besudil is to control the tissue damage process caused by abnormal activation of T cells and B cells. In chronic GVHD, this pathological state often manifests as skin sclerosis, decreased lung function, oral mucositis, or limited joint mobility, which seriously affects the patient's quality of life. Besudil helps restore the balance of the immune system by inhibiting ROCK2 signaling, reducing the release of pro-inflammatory cytokines such as IL-17 and IL-21, and enhancing the function of regulatory T cells (Treg). This regulatory effect not only reduces local inflammation, but also combats the process of organ fibrosis in the chronic stage, which has long-term therapeutic significance.

In addition, besudil has good oral bioavailability and does not require intravenous infusion, making it suitable for long-term outpatient management. Its side effect spectrum is relatively mild, mostly mild gastrointestinal discomfort, mild elevation of liver enzymes, etc., which can be controlled through regular monitoring and individualized dose adjustment. Because of its novel mechanism and controllable safety, besudil is considered an important breakthrough in the treatment of chronic immune complications in recent years, providing new hope for patients who have failed previous treatments or are dependent on hormones.

Currently, the potential application of besudil in other diseases such as systemic sclerosis, idiopathic pulmonary fibrosis and even some autoimmune diseases is also being explored globally. Although it is still in the clinical research stage, the universality of its target and the plasticity of its effects leave broad room for future expansion of indications.

Reference: https://www.drugs.com/pro/rezurock.html